Q&A: Pharmacists Play Essential Role in Insulin Therapy Success
Drug Topics
JULY 15, 2025
Pharmacists, pharmacy students, or technicians can assist with insurance navigation, advocating for prior authorizations if needed.
FDA Hospitals Insurance 
Q&A: How Advancements in GLP-1s, CGM Impact Insulin Management
Drug Topics
JULY 15, 2025
READ MORE: Insulin Advancements Led to Safer Surgeries, Shorter Hospital Stays Drug Topics : How has the administration of insulin management been impacted by medical advancements in things like CGM and GLP-1 medications? They will have insurance coverage, and that has helped tremendously to be able to adjust insulin doses.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Flu Vaccines Are a Go
Pharmacy Times
JULY 16, 2025
Importantly, ACIP’s recommendations do have a strong influence, if not a mandate, on health insurance companies with respect to coverage and co-payments for immunizations as well as the Vaccines for Children Program, which provides coverage for access to vaccines for those who are 18 years or younger.
Vaccines 
100
100 
FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
Pharmaceutical Technology
JUNE 25, 2025
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects the elderly. In February 2025, the FDA accepted Dupixent’s supplemental biologics licence application (sBLA) for priority review.
FDA 52
52 
How much is fluorouracil without insurance?
The Checkup by Singlecare
JULY 2, 2025
Without insurance, one 40 gm tube of fluorouracil 5% topical cream costs about $363. How much does fluorouracil cost without insurance? Your cost for fluorouracil may vary depending on your diagnosis, treatment regimen, length, and insurance coverage. Without insurance, it can cost around $233 for a single 40 g tube of cream.
Insurance 52
52 
Forteo generic: Availability, cost, and more
The Checkup by Singlecare
JULY 10, 2025
It’s also expensive, costing over $5,000 per month without insurance. Given the high price, many people turn to insurance for generic drugs to help lower the cost of treatment. That is, they have the same active ingredients, FDA-approved uses, and dosages administered with a prefilled pen. Is a generic for Forteo available?
Dosage 52
52 
Compounded semaglutide side effects
The Checkup by Singlecare
FEBRUARY 17, 2025
Its not safe or effective, according to the Food and Drug Administration (FDA), and it may lead to serious health problems. Although these medications are effective, the FDA has not yet approved generic versions, meaning people can only get a prescription for semaglutide under its brand name. Is compounded semaglutide safe?
Compounding 52
52 
Gabapentin overdose in dogs: Symptoms and prevention
The Checkup by Singlecare
DECEMBER 30, 2024
Additionally, gabapentin is typically used as a human medicine; its prescribed off-label for dogs since it doesnt have FDA approval for them yet. Toxicity depends on multiple things, such as the dose ingested, the dogs size, and overall health, adds Dr. Nita Vasudevan, DVM, a veterinarian and veterinary consultant for Embrace Pet Insurance.
Dosage 59
59 
Farxiga vs. Jardiance: Key differences, uses, and side effects
The Checkup by Singlecare
FEBRUARY 4, 2025
Food and Drug Administration (FDA) to manage Type 2 diabetes mellitus. A study was designed to compare the use of Invokana (canagliflozin), another SGLT2 inhibitor, or Farxiga with Jardiance for occurrence of myocardial infarction (MI) or stroke, or heart failure hospitalization. Each has additional specific uses as described below.
Hospitals 52
52 
MSD receives FDA approval for Enflonsia to prevent RSV
Pharmaceutical Technology
JUNE 10, 2025
MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Can pharma tariffs “Make America Manufacture Again”? Credit: MargJohnsonVA/Shutterstock.
FDA 52
52 
Pharmacists Push Forward: Innovative Clinical Solutions Highlighted at McKesson ideaShare 2025
Pharmacy Times
JULY 12, 2025
1 Howard’s team built their telehealth service in collaboration with hospitals and health systems, especially to tackle the issue of hospital readmissions for Medicare and Medicaid patients—each of which can cost hospitals thousands of dollars.
Vutrisiran marks first silencer approved for ATTR-CM
Pharmaceutical Technology
JUNE 12, 2025
Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia
Pharmaceutical Technology
JUNE 9, 2025
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for YOLT-101 to treat heterozygous familial hypercholesterolemia (HeFH). Credit: aipicte/Shutterstock. Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
FDA 52
52 
Does Medicaid cover Trintellix?
The Checkup by Singlecare
NOVEMBER 4, 2024
Trintellix (vortioxetine) is a brand-name prescription medication that was approved by the Food and Drug Administration (FDA) in 2013 to treat major depressive disorder (MDD) in adults. It helps people with limited income pay for doctor visits, hospital stays, and prescription drugs. This includes coverage for Trintellix.
Insurance 52
52 
Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product
Pharmacy Times
JULY 4, 2025
SHOW MORE Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization. The study's primary objective was to assess reversion rates to Humira, with 9% reverting after three months, while 91% remained on biosimilars or switched to alternatives.
Mosanna Therapeutics gains $80m to advance OSA nasal spray
Pharmaceutical Technology
JUNE 10, 2025
Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis
Pharmacy Times
JULY 1, 2025
Tafamidis, a selective transthyretin stabilizer, significantly reduces mortality and hospitalizations in ATTR-CM patients. Tafamidis] was compared to placebo and reduced all-cause mortality by 30% and [cardiovascular] hospitalizations by 32% over 30 months.
Pharmacy Policy Updates for June 2025
Pharmacy Times
JUNE 16, 2025
Second, it does not address the core issues of higher prices, such as the use of rebates by insurers. Kennedy Jr, is permitted to develop a new rule that ties American drug prices to those of other nations. First, this may be blocked by a federal judge again. And finally, the most favored nation pricing model is unworkable.”—
Tisento’s MELAS treatment receives fast track status from FDA
Pharmaceutical Technology
JUNE 18, 2025
Tisento Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its investigational oral medicine, zagociguat, for mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), a rare mitochondrial disease. Credit: Volha_R/Shutterstock.
FDA 52
52 
Opioid statistics, 2025
The Checkup by Singlecare
JUNE 24, 2025
The Food and Drug Administration (FDA) has approved certain opioids for: Relief of mild to moderate severe pain (e.g., The Food and Drug Administration (FDA) has approved certain opioids for: Relief of mild to moderate severe pain (e.g., This cost included hospital visits, healthcare provider visits, and medication.
FDA 52
52 
Building Intelligent Pharma Supply Chain Management with Real-World Data
Pharmaceutical Commerce
JUNE 17, 2025
Intelligent medication management systems using RWD help hospitals forecast demand, respond to crises, and minimize medication expiration and loss, ultimately improving patient care and operational efficiency. The FDA oversees over 23,000 prescription drug products approved for marketing in the US 1 and ultimately, an estimated 361.3
Big pharma braces for revenue headwinds as patent expiries loom
Pharmaceutical Technology
JULY 4, 2025
Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
Chemotherapy 52
52 
OTC Assessments With Recommendations and Counseling Should Be a Billable Encounter
Pharmacy Times
JUNE 17, 2025
That means that pharmacists in the twilight of their career have, at some point, filled a prescription, engaged in drug utilization review, filed insurance claims, and counseled per the Omnibus Budget Reconciliation Act of 1990 regulations for many of the products now found in front of the counter. Am J Health Syst Pharm. 2024;81(14):583-598.
Expanding Access: Digital Therapeutics and the Evolving Role of Pharmacists
Pharmacy Times
JULY 3, 2025
In an interview with Pharmacy Times®, Areo Nazari, PharmD, CEO at CaryHealth, discussed how prescription digital therapeutics (PDTs) are FDA-approved, software-based treatments that offer alternatives or complements to traditional therapies. Pharmacy Times: Can you give a brief overview of PDTs?
ADA 2025: Ready-to-Use Glucagon Empowers Diabetes Patient Safety
Pharmacy Times
JUNE 23, 2025
Goldman and Isaacs emphasize the importance of identifying at-risk patients through various health care touchpoints, including doctor's offices and pharmacies, and advocate for routine glucagon prescription and insurance coverage. But I also think everyone should have a ready-to-use cover on their insurance.
FDA approves label updates for BMS’ CAR T cell therapies
Pharmaceutical Technology
JUNE 27, 2025
Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has given approval to label updates for its CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso-cel) and Abecma (idecabtagene vicleucel; ide-cel) to treat multiple myeloma. Credit: Saiful52 / Shutterstock.
Labelling 52
52 
Navigating Rilonacept Therapy: Dose Adjustments, Discontinuation, and Patient Support Strategies
Pharmacy Times
JULY 1, 2025
We look at multiple factors, including how stable their disease is, the number of flares patients have experienced, if any, and if they are at higher risk of further flares, hospitalizations, or disease progression.
FDA approves KalVista’s Ekterly for hereditary angioedema
Pharmaceutical Technology
JULY 7, 2025
The US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals’ Ekterly (sebetralstat) as the first and only oral on-demand medication for acute attacks of hereditary angioedema (HAE) in adults and in children aged 12 years and above. Credit: KalVista Pharmaceuticals/Business Wire.
FDA 122
122 
Mounjaro vs. Farxiga: Differences and similarities explained
The Checkup by Singlecare
JULY 17, 2025
Adults Adults and children 10 and older Mounjaro and Farxiga are approved by the Food and Drug Administration (FDA) to manage Type 2 diabetes mellitus. Unlike Mounjaro, Farxiga is also FDA approved to protect the kidneys in people with known kidney problems and lower the risk of hospitalization in people with heart failure.
Insurance 52
52 
Madrigal poised to enter European MASH market after CHMP endorsement
Pharmaceutical Technology
JUNE 20, 2025
Madrigal accessed a large US market when it won accelerated US Food and Drug Administration (FDA) approval in March 2024 for the first MASH treatment in the region. Rezdiffra is already available in the US for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness
Pharmaceutical Technology
JULY 1, 2025
Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
Packaging 52
52 
Piramal Pharma announces $90m investment to expand US sites
Pharmaceutical Technology
JULY 1, 2025
Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
Pharma Marketing Resources
Pharma Marketing Network
MARCH 11, 2025
Strict guidelines from the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) require marketers to ensure transparency and accuracy in all communications. FDA Guidelines and Promotional Review Committees Understanding FDA regulations is critical for all pharma marketing professionals.
HIPAA 52
52 
Fentanyl facts and statistics
The Checkup by Singlecare
MAY 6, 2025
Fentanyl may also be prescribed off-label, meaning for a purpose other than what the Food and Drug Administration (FDA) approved it for. FDA, 2024) Brand names of fentanyl include Sublimaze, Actiq, Fentora, and Duragesic. As of Sept. 30, 2024 , TIRF manufacturers stopped production of these forms of medications.
Labelling 52
52 
FDA gives TSND-201 breakthrough therapy designation for PTSD
Pharmaceutical Technology
JULY 10, 2025
Transcend Therapeutics has announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to TSND-201, a rapid-acting neuroplastogen, for the treatment of post-traumatic stress disorder (PTSD). Credit: Andrey_Popov/Shutterstock. Stay proactive with real-time data and expert analysis.
FDA 52
52 
How much does Rinvoq cost with Medicare?
The Checkup by Singlecare
JULY 7, 2025
New changes to Medicare in 2025 Medicare is a federal health insurance program developed for people 65 and older and younger individuals with certain disabilities. It provides access to hospital care, medical services, and prescription drug coverage. This extra documentation can help the insurer decide if Rinvoq is medically necessary.
Insurance 52
52 
European pharma needs scalable models to succeed in US
Pharmaceutical Technology
JUNE 17, 2025
Give your business an edge with our leading industry insights. Give your business an edge with our leading industry insights.
ADA 2025: Breaking Barriers in Glucagon Prescription
Pharmacy Times
JUNE 22, 2025
They highlighted that only 4% of the 15 million people using insulin have a glucagon prescription, largely due to misconceptions about ease of use, cost, and insurance coverage. My insurance isn't going to cover it, and so people don't even try to prescribe it.
Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold
Pharmaceutical Technology
JULY 2, 2025
US market provides uptake hint The US Food and Drug Administration (FDA) approved Alyftrek in December 2024 , providing a window into market dynamics for the drug. With this approval, we are one step closer to our ultimate goal of restoring normal levels of CFTR function in people living with cystic fibrosis.”
Packaging 52
52 
Does Kaiser cover Wegovy?
The Checkup by Singlecare
JUNE 5, 2025
Wegovy (semaglutide) is a prescription glucagon-like peptide-1 (GLP-1) medication approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain weight reduction in people ages 12 and older with a diagnosis of obesity or in adults who are overweight with a weight-related health condition.
Insurance 52
52 
FDA publishes more than 200 archived CRLs for transparency
Pharmaceutical Technology
JULY 11, 2025
In a move towards transparency, the US Food and Drug Administration (FDA) has published more than 200 archived complete response letters (CRLs), which detail reasons for non-approval of drug applications submitted between 2020 and 2024. How will RFK Jr’s American dream for vaccines play out? Credit: Tada Images/Shutterstock.
FDA 52
52 
Revolution Medicines partners Royalty Pharma on $2bn funding
Pharmaceutical Technology
JUNE 25, 2025
The first tranche will be received by Revolution, following US Food and Drug Administration (FDA) approval of daraxonrasib to treat metastatic PDAC by January 2028. The debt facility portion consists of three tranches totalling up to $750m linked directly to daraxonrasib’s commercial milestones.
Packaging 52
52 
Out of Shortage, Into Controversy: The Fight Over GLP-1 Compounding
Pharmacy Times
JULY 18, 2025
Rumore, PharmD, Esq, MS, LLM, FAPhA Key Takeaways The removal of tirzepatide and semaglutide from the FDA's shortage list impacts 503A compounders, requiring adherence to complex legal and regulatory frameworks. SHOW MORE GLP-1 compounding faces legal challenges, evolving FDA rules, and heightened enforcement risks.
Compounding 73
73 
Study Reveals Alarming Gaps in HER2 Therapy Access for Patients With Breast Cancer
Pharmacy Times
JULY 1, 2025
Utilization of HER2 therapies is positively associated with private insurance, academic facility treatment, and recent diagnosis years. Disparities in HER2 therapy access are linked to rural treatment, Black race, Medicare insurance, and older age. 3 Among the patients, approximately 75.8% in 2013 to 80.9%
Let's personalize your content